This paper describes work to improve the targeting of drug delivery for such infections by modifying intranasal spray usage protocols. Computational fluid dynamic studies and experimental validation work show that with an improved protocol, involving more shallowed (almost horizontal) angling of the intranasal spray, drug delivery to the nasopharyngeal viral infection ‘hot spot’ can be doubled. The optimal droplet size for drug delivery for such applications is discussed, and the robustness of the developed protocol is highlighted, with respect to the consistency of drug delivery.
Learn more about Aptar Pharma Expertise
in Nasal Drug Delivery
This Might Also Be of Interest
Optimising Preclinical Studies for Intranasal and Pulmonary Programmes
Publications, Pharmaceutical, Device Innovations, Market Insights, Product Solutions
Targeted Aerosol Delivery to NALT Using BiVax Intranasal Atomizer
Publications, Pharmaceutical, Device Innovations, Market Insights, Product Solutions
PureHale® & The Future of Fine Mist Dispensers for Upper Airway Treatments
Publications, Pharmaceutical, Device Innovations, Brand Differentiation, Market Insights, Product Solutions
Acute Migraine Relief: Nose-to-Brain Delivery with Lipid Nanoparticles
Publications, Pharmaceutical, Device Innovations, Market Insights, Product Solutions